1 / 25

Prospective evaluation of Innovance D-dimer in the exclusion of venous thromboembolism [VTE].

Prospective evaluation of Innovance D-dimer in the exclusion of venous thromboembolism [VTE]. Robert Gosselin, CLS Department of Clinical Pathology and Laboratory Medicine University of California, Davis Health System Sacramento, CA. D-dimer Indicates clot formation

jacquelinef
Download Presentation

Prospective evaluation of Innovance D-dimer in the exclusion of venous thromboembolism [VTE].

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Prospective evaluation of Innovance D-dimer in the exclusion of venous thromboembolism [VTE]. Robert Gosselin, CLS Department of Clinical Pathology and Laboratory Medicine University of California, Davis Health System Sacramento, CA

  2. D-dimer • Indicates clot formation • Indicates clot degradation • D-dimer test commonly used for exclusion: • Pulmonary embolism • Deep vein thrombosis • Consumptive coagulopathy • Aortic dissection

  3. Innovance D-dimer and Stratus CS D-dimer new test from Siemen Healthcare • Prospective study in the US to validate cut-off for excluding PE and DVT

  4. 3 sites in US • Duke University • Cleveland Clinic • UC Davis • Total enrollment all sites • 550 PE • 480 DVT

  5. Inclusion criteria • First clinically suspected PE and/or DVT • Objective testing • Diagnostic algorithms • Radiographic studies • Capable of giving informed consent • Agree to 3 month follow-up for patients with negative imaging studies.

  6. Exclusion criteria • Under 18 years of age • Pregnant • Previous Hx of PE or DVT • Resolved symptoms >72 hours before presenting to ED • Oral anticoagulation • 3 month f/u not available • Inpatient • Prisoners

  7. Clinical Probability for DVT Active cancer +1 Paralysis, paresis, recent casting of leg +1 Bedridden (>3 days) or major (>12 weeks) +1 Entire leg swollen +1 Calf swelling (>3cm) compared to other leg +1 Pitting edema greater in symptomatic leg +1 Collateral nonvaricose superficial veins +1 Localized tenderness along deep venous system +1 Previously documented DVT +1 Alternative Dx as or more likely than DVT -2 Score: DVT unlikely <2 DVT likely >2 Wells PS, et al Lancet 1997; 350:1795-98; N Engl J Med 2003;349: 1227-35

  8. Clinical Probability for PE Clinical signs and symptoms of DVT +3 Heart rate >100/min +1.5 Hemoptysis +1 Active cancer +1 Bedridden (>3 days) or major (>12 weeks) +1.5 Previously history of DVT or PE +1.5 PE most likely diagnosis +3 Score: Low <2 Moderate 2-6 High >6 Wells PS, et al Thromb Haemost 2000; 83:416-20.

  9. DVT Algorithm Compression US Positive Negative Low prob Serial CUS (5-8 days) Mod or High Prob Positive Negative 3 month f/u Positive VTE Negative VTE DVT Positive DVT Negative

  10. PE Algorithm Spiral CT or Angiogram Positive Negative 3 month f/u Positive VTE Negative VTE PE Positive PE Negative

  11. After informed consent • Blood collected • 3.2% sodium citrate • Lithium heparin (Stratus only) • If testing within 4 hours of collection • Whole blood heparin on Stratus • Plasma testing on other analyzers • If testing not completed within 4 hours of collection • Samples processed and refrigerated • Testing completed within 24 hours of collection

  12. Testing performed on: Sysmex analyzers CA560 CA1500 CA7000 BCS Stratus (heparin and citrate testing) [Delayed testing---CS2000i]

  13. As of May 11, 2009 • 381 patients enrolled • 353 with demographics complete • 284 with 3 mo f/u • 2 withdrawn • One patient declined participation after testing completed [1 month later] • One patient had imaging studies canceled after enrollment • 4 pending 3 month f/u • 8 patients expired • 0/8 with normal D-dimer levels

  14. 37% males [91/248] Median age 51.5 years [range 19-81 years] Patients with PE studies • Probability scores • Low probability 62% [154/248] • Moderate probability 33% [82/248] • High probability 3% [7/248] • No score performed 2% [5/248] Patients with DVT studies • Probability scores • Unlikely 64.4% [94/146] • Likely 30.8% [45/146] • No score performed 4.7% [7/146]

  15. Of the 353 patients with demographics: • 70.2% [248/353] tested for PE • 238 with spiral CT • 12 with V/Q scan • 25 with PE [10.5%] • 41.4% [146/353] CUS for DVT • 13 with DVT [9.6%] 37 patients evaluated for PE and DVT • 30 with CT and CUS • 6 with VQ and CUS • 1 with CUS, CT and VQ • 3 patients with both DVT and PE

  16. 3.7 Innovance D-dimer mg/L 0.8 No VTE VTE

  17. PE Probability DVT Probability Innovance D-dimer, mg/L Low Mod High Unlikely Likely

  18. Data for all patients enrolled SCS-H Heparin sample on Stratus SCS-C Citrate sample on Stratus

  19. Innovance D-dimer in all VTE SCS-H Heparin sample on Stratus SCS-C Citrate sample on Stratus

  20. Patients evaluated for PE N=248 SCS-H Heparin sample on Stratus SCS-C Citrate sample on Stratus

  21. Innovance D-dimer in PE SCS-H Heparin sample on Stratus SCS-C Citrate sample on Stratus

  22. Patients evaluated for DVT N=146 SCS-H Heparin sample on Stratus SCS-C Citrate sample on Stratus

  23. Innovance D-dimer in DVT SCS-H Heparin sample on Stratus SCS-C Citrate sample on Stratus

  24. Summary • Poor positive predictive value of D-dimer with VTE • Acceptable negative predictive value for Innovance D-dimer in excluding VTE in outpatients • Need more data for PE sensitivity • Weakness • Few positive samples in subset analysis

  25. Fellow collaborators at UC Davis • Edward Panacek, MD, MPH • Abhi Gorhi, MS, CCRP • Shari Nichols, CCRP • Allyson Sage, RN • Leslie Freeman, CLS • Andrea Picazo, CCRP

More Related